Clarithromycin as Adjuvant to Periodontal Debridement (NCT02829983) | Clinical Trial Compass
CompletedNot Applicable
Clarithromycin as Adjuvant to Periodontal Debridement
40 participantsStarted 2014-03
Plain-language summary
To assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.
Who can participate
Age range18 Years – 35 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* diagnosis of Generalized Aggressive Periodontitis
* presence of ≥20 teeth
* presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them)
* good general health
* \<35 years of age
* agree to participate in the study and sign a written consent
Exclusion Criteria:
* pregnant or lactating
* suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease
* received antimicrobials in the previous 6 months
* taking long-term anti-inflammatory drugs
* received a course of periodontal treatment within the last 12 months
* smoked
What they're measuring
1
Clinical Attachment Level
Timeframe: 6 months
Trial details
NCT IDNCT02829983
SponsorUniversidade Estadual Paulista Júlio de Mesquita Filho